The posting, in Summit Therapeutics's own words
archived Oct 24, 2026About Summit:
Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. Overview of Role The Medical Writer, Medical Communications & Publications will be responsible for developing high-quality scientific and medical communications that support the dissemination of clinical data and the medical strategy. This role will lead and support the development of scientific publications and other Medical Affairs deliverables , translating complex clinical and scientific data into clear, accurate, and balanced scientific narratives. The Medical Writer will collaborate closely with Medical Strategy Directors, Medical Training, Clinical Development, Biostatistics, Regulatory, and other cross-functional partners, as well as external investigators, authors, and medical communications agencies when relevant.
Responsibilities
Develop Medical Affairs materials, including slide decks, data summaries, FAQs, field medical resources, and internal scientific training materials . Support the development of abstracts, manuscripts, posters, oral presentations, and other publication deliverables from concept through submission and publication. Partner with Medical Affairs colleagues to execute global publication plans and scientific communication strategies . Translate complex clinical trial results and scientific information into clear, accurate, balanced, and scientifically rigorous communications. Conduct literature reviews and synthesize published and emerging scientific data to support publications and Medical Affairs initiatives. Work directly with investigators, external authors, and internal subject-matter experts to facilitate content development, review, revision, and approval. Review clinical data, tables, figures, statistical outputs, and source materials to ensure scientific accuracy and consistency. Coordinate publication and medical communication activities with internal teams and external agencies, ensuring projects meet agreed-upon timelines and quality standards. Maintain consistency of scientific language, data presentation, and key scientific messages across Medical Affairs communications. Ensure publication activities follow applicable standards and ethical principles, including Good Publication Practice (GPP) and ICMJE recommendations . Support congress-related Medical Affairs activities and the timely communication of new clinical and scientific data.